spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  ocular inflammation 

 HSMN NewsFeed - 21 May 2024
Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili(TM). Enters U.S. Ophthalmology Market
Biopharmaceuticals Generics Ophthalmology FDA
 HSMN NewsFeed - 21 Oct 2022
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 8 Aug 2022
Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 29 Jun 2022
EYLEA(R) (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Apr 2021
FDA Approves Bausch & Lomb ClearVisc(TM) Dispersive Ophthalmic Viscosurgical Device
Devices Ophthalmology FDA
 HSMN NewsFeed - 4 Sep 2019
REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 13 Aug 2019
FDA Approves EYLEA(R) (aflibercept) Injection Prefilled Syringe
Biopharmaceuticals Drug Delivery Ophthalmology FDA
 HSMN NewsFeed - 26 Mar 2019
Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 4 Jan 2019
Oculis Raises CHF15.5 Million in an Extension of its Series B Financing Round - Total Raised CHF35.5 Million
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 25 Oct 2018
EYLEA(R) (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 13 Sep 2018
FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 17 Aug 2018
FDA Approves EYLEA(R) (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 10 May 2018
Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 24 Apr 2018
Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 19 Mar 2018
EYLEA(R) (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 21 Dec 2017
Santen Receives Complete Response Letter from U.S. FDA for Intravitreal Sirolimus (DE-109)
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 12 Dec 2017
Eyevensys Appoints Dr. Patricia Zilliox as Chief Executive Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 4 Sep 2017
Eyevensys Appoints Dr Ronald R. Buggage as Chief Medical Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 1 May 2017
Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 22 Mar 2017
Allergan Announces Availability of RESTASIS MULTIDOSE(TM) (Cyclosporine Ophthalmic Emulsion) 0.05% -- the First FDA-Approved Preservative Free Prescription Eye Drop Available in a Multidose Bottle
Biopharmaceuticals Ophthalmology Product Launch
 HSMN NewsFeed - 21 Mar 2017
Eyevensys Appoints Leading Life Sciences Executive and Ophthalmology Expert Dr. Garth Cumberlidge as Chairman
Biopharmaceuticals Devices Ophthalmology Personnel
 HSMN NewsFeed - 21 Feb 2017
Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 13 Oct 2016
Ocular Therapeutix(TM) and Regeneron Enter Into Strategic Collaboration to Develop Sustained Release Formulation of Aflibercept for the Treatment of Wet AMD and Other Serious Retinal Diseases
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 15 Sep 2016
Eyevensys Announces Series A Extension Bringing Total Capital Raised to €9 Million
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 30 Jun 2014
Allergan Announces R&D Pipeline Update and U.S. FDA Approval; Company to Host Conference Call Today, Monday, June 30th at 10:30 AM ET
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 27 Jun 2014
EYLEA(R) (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 10 Feb 2014
Two-Year Results From Phase 3 VISTA Trial of EYLEA(R) (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 6 Jan 2014
Kala Pharmaceuticals Appoints Howard B. Rosen as Chairman of the Board of Directors
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 18 Dec 2013
InSite Vision Announces Positive Confirmatory Phase 3 Results for BromSite(TM) for the Reduction of Inflammation and Pain after Cataract Surgery
Biopharmaceuticals Drug Delivery Ophthalmology Surgery
 HSMN NewsFeed - 18 Dec 2013
Regeneron Announces FDA Acceptance of EYLEA(R) (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 22 Nov 2013
EYLEA(R) (aflibercept) Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 24 Oct 2013
Celsus Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jul 2013
EYLEA(R) (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion in Europe
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 28 Feb 2013
Kala Pharmaceuticals Secures $11.5 Million in Series A Financing
Biopharmaceuticals Drug Delivery Venture Capital
 HSMN NewsFeed - 19 Feb 2013
Regeneron and Bayer Initiate Phase 3 Trial of EYLEA(R) (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 12 Dec 2012
Sucampo Announces FDA Approval of an sNDA for RESCULA(R) (unoprostone isopropyl)
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 6 Dec 2012
EYLEA(R) (aflibercept) Submitted for EU Marketing Authorization for the Treatment of Macular Edema Following Central Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 27 Nov 2012
Kala Pharmaceuticals Appoints Dr. Bernard Gilly to Its Board of Directors
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 27 Nov 2012
EYLEA(R) (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Europe
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 8 Mar 2012
Regeneron and Bayer Announce Approval of EYLEA(R) (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration in Australia
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 13 Oct 2011
ISTA Pharmaceuticals Announces Statistically Significant Phase 3 Results for PROLENSA(TM)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 17 Nov 2010
ISTA Pharmaceuticals Granted Three-Year Market Exclusivity for BROMDAY
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 31 Aug 2010
Allergan, Inc. Receives FDA Approval for LUMIGAN(R) 0.01% as First-Line Therapy Indicated for the Reduction of Elevated Intraocular Pressure in Glaucoma Patients
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 3 Jun 2010
Bausch & Lomb Acquires Zirgan(R) (Ganciclovir Ophthalmic Gel 0.15%) From Sirion Therapeutics for the Treatment of Herpetic Keratitis
Biopharmaceuticals Ophthalmology Acquisitions
 HSMN NewsFeed - 28 Sep 2009
Bausch & Lomb Subsidiaries and CROMA will Co-Promote Bromfenac Ophthalmic Solution in Europe
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 16 Sep 2009
Sirion Therapeutics Announces FDA Approval of Zirgan(TM) (Ganciclovir Ophthalmic Gel) 0.15% for Herpetic Keratitis
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 2 Jan 2009
FDA Announces Class I Recall of Ophthalmic Surgical Device
Devices Ophthalmology Surgery FDA Product Recall
 HSMN NewsFeed - 24 Jun 2008
Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 9 Apr 2008
Novagali Pharma Announces the Launch of Cationorm(R)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 12 Nov 2007
ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 25 Oct 2007
Sirion Therapeutics Announces Positive Phase III Results for Difluprednate
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 8 Feb 2007
ISTA Pharmaceuticals Announces Positive Preliminary Xibrom(TM) Once-daily Formulation Clinical Results From U.S. Phase III Trials
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 4 Oct 2006
New England Journal of Medicine Publishes Data From Lucentis Pivotal Phase III Studies in Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 24 Jul 2006
Sirion Therapeutics Acquires U.S. License to Develop New Ophthalmic Compound
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 30 Jun 2006
FDA Approves LUCENTIS for the Treatment of Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 2 Jun 2006
Preliminary Results from a Phase IIIb Study Showed Patients With Wet AMD Treated With Lucentis Quarterly Experienced a 16-Letter Benefit Over the Control Group at One Year
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 30 May 2006
ISTA Pharmaceuticals Is Initiating Phase III Clinical Trials of a New Once-Daily Formulation of Xibrom(TM) for the Treatment of Ocular Pain and Inflammation Following Cataract Surgery
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 4 May 2006
ISTA Pharmaceuticals(R) Announces Study Indicating Twice-Daily Dosing of Xibrom(TM) as Equivalent to Four Times a Day of Other Treatments
Biopharmaceuticals Ophthalmology
Return to NewsFeed  

 Additional items found! 18

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 18 additional stories matching:
ocular inflammation
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!